Arrestins in the Cardiovascular System - Progress in Molecular Biology and Translational Science - page 320

36. Kim J, Ahn S, Rajagopal K, Lefkowitz RJ. Independent beta-arrestin2 and Gq/protein
kinase Czeta pathways for ERK stimulated by angiotensin type 1A receptors in vascular
smooth muscle cells converge on transactivation of the epidermal growth factor recep-
tor. J Biol Chem . 2009;284:11953 - 11962.
37. Ahn S, Kim J, Hara MR, Ren XR, Lefkowitz RJ. Beta-arrestin-2 mediates anti-
apoptotic signaling through regulation of BAD phosphorylation. J Biol Chem .

2009;284:8855 - 8865.
38. Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Soltys S, Koch WJ. An adrenal beta-
arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone
production in vitro and in vivo. Proc Natl Acad Sci USA . 2009;106:5825 - 5830.
39. Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Koch WJ. Adrenal beta-arrestin 1
inhibition in vivo attenuates post-myocardial infarction progression to heart failure and
adverse remodeling via reduction of circulating aldosterone levels. J Am Coll Cardiol .
2011;57:356 - 365.
40. Morris GE, Nelson CP, Standen NB, Challiss RA, Willets JM. Endothelin signalling in
arterial smooth muscle is tightly regulated by G protein-coupled receptor kinase 2.
Cardiovasc Res . 2010;85:424- 433.
41. Morris GE, Nelson CP, Brighton PJ, Standen NB, Challiss RA, Willets JM. Arrestins 2
and 3 differentially regulate ETA and P2Y2 receptor-mediated cell signaling and migra-
tion in arterial smooth muscle. Am J Physiol Cell Physiol . 2012;302:C723 - C734.
42. Barak LS, Oakley RH, Laporte SA, Caron MG. Constitutive arrestin-mediated desen-
sitization of a human vasopressin receptor mutant associated with nephrogenic diabetes
insipidus. Proc Natl Acad Sci USA . 2001;98:93 - 98.
43. Rochdi MD, Vargas GA, Carpentier E, et al. Functional characterization of vasopressin
type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus
and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments.
Mol Pharmacol . 2010;77:836 - 845.
44. Walters RW, Shukla AK, Kovacs JJ, et al. Beta-arrestin1 mediates nicotinic acid-
induced flushing, but not its antilipolytic effect, in mice. J Clin Invest .

2009;119:1312 - 1321.
45. Schaff M, Receveur N, Bourdon C, et al. b -arrestin-1 participates in thrombosis and
regulates integrin aIIb b 3 signalling without affecting P2Y receptors desensitisation and
function. Thromb Haemost . 2012;107:735 - 748.
46. Morris GE, Nelson CP, Everitt D, et al. G protein-coupled receptor kinase 2 and
arrestin2 regulate arterial smooth muscle P2Y-purinoceptor signalling. Cardiovasc
Res . 2011;89:193 - 203.
47. Li D, D'Angelo L, Chavez M, Woulfe DS. Arrestin-2 differentially regulates PAR4 and
ADP receptor signaling in platelets. J Biol Chem . 2011;286:3805 - 3814.
48. Kukkonen JP. Regulation of receptor-coupling to (multiple) G proteins. A challenge
for basic research and drug discovery. Receptors Channels . 2004;10:167 - 183.
49. Brodde OE. Beta-adrenoceptors in cardiac disease. Pharmacol Ther . 1993;60:405 - 430.
50. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of b 1- and b 2-
adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive
G protein. Circulation . 1999;100:2210 - 2212.
51. Chesley A, Lundberg MS, Asai T, et al. The b 2-adrenergic receptor delivers an anti-
apoptotic signal to cardiac myocytes through Gi-dependent coupling to pho-
sphatidylinositol 3-kinase. Circ Res . 2000;87:1172- 1179.
52. ZhuWZ, Zheng M, KochWJ, Lefkowitz RJ, Kobilka BK, Xiao RP. Dual modulation
of cell survival and cell death by b 2-adrenergic signalling in adult mouse
cardiomyocytes. Proc Natl Acad Sci USA . 2001;98:1607 - 1612.
53. Dorn II GW, Tepe NM, Lorenz JN, Koch WJ, Liggett SB. Low- and high-level trans-
genic expression of b 2-adrenergic receptors differentially affect cardiac hypertrophy